World-Class Regenerative & Stem Cell Therapy in India

Context: Evaluated whether intra-articular injections of umbilical cord-derived MSCs improved pain scores and joint mobility compared to hyaluronic acid. Repeated injections led to statistically significant reductions in WOMAC pain scores and improvements in function over a 12-month follow-up without serious adverse events.

Context: A landmark Phase 3 trial evaluating allogeneic expanded adipose-derived stem cells (darvadstrocel) for treatment-refractory perianal fistulas. The treated group achieved a 50% combined clinical and MRI-confirmed remission rate at 24 weeks compared to 34% in the control group, leading to formal European regulatory approval.

Context: Investigated two repeated intrathecal injections of autologous bone marrow-derived MSCs alongside standard riluzole therapy. Treated patients demonstrated a significant temporary slowing of functional decline on the ALSFRS-R score at 4 and 6 months, mediated by a decrease in proinflammatory cerebrospinal fluid cytokines.

Context: A multicenter European clinical trial evaluating bone marrow MSC infusions for severe, life-threatening acute GvHD unresponsive to high-dose corticosteroids. Over 70% of treated patients showed clinical response, with significantly improved overall survival rates in responders.

Context: Assessed the safety and neuroprotective impact of autologous bone marrow MSC infusions in patients with visual pathway involvement. The study demonstrated safety and reported improvements in visual acuity and visual evoked response latency, pointing to structural paracrine support.

Context: Evaluated intravenous and intrathecal infusions of allogeneic umbilical cord-derived MSCs alongside standard rehabilitation for patients with stroke sequelae. Patients receiving cellular therapy demonstrated significant improvements in National Institutes of Health Stroke Scale (NIHSS) scores and Functional Independence Measures (FIM) over 12 months compared to rehabilitation alone.

Context: A large-scale randomized trial investigating transendocardial injections of allogeneic mesenchymal precursor cells (MPCs) in chronic heart failure with reduced ejection fraction (HFrEF). While total recurrent hospitalizations did not decrease, cellular therapy significantly reduced the long-term risk of non-fatal myocardial infarction and stroke in patients with baseline systemic inflammation.

Context: A randomized, placebo-controlled trial evaluating allogeneic bone marrow-derived mesenchymal precursor cells in patients with type 2 diabetes and stage 3–4 chronic kidney disease. A single infusion was well-tolerated and stabilized estimated glomerular filtration rate (eGFR) decline while significantly reducing systemic inflammatory biomarkers.

Context: Examined the immunomodulatory effects of intravenous allogeneic umbilical cord MSCs in patients experiencing acute pulmonary inflammation and severe respiratory failure. Treated cohorts showed significant reductions in circulating inflammatory cytokines (IL-6, TNF-alpha) and improved oxygenation indexes and recovery times.

Context: A long-term clinical trial examining allogeneic umbilical cord-derived MSC transplants in patients with active, treatment-resistant lupus nephritis. Treatment led to sustained clinical remission, stabilization of renal parameters, and marked decreases in SLEDAI (disease activity) scores over four years of post-treatment follow-up.